therapeutic INRs
- AI-extracted — pending human review
- Source-authored record; platform synthesis is not enabled for this record.
- Publication status: published.
Authors reported OR 4.32; 95% CI 1.13 to 17.44; p = 0.015. No effect is calculated by the platform.
randomized trial. Population: Patients with an international normalized ratio (INR) between 4.5 and 10.0. Subject: oral vitamin K. Comparator: subcutaneous vitamin K. Source window: on the day after study drug administration. Scope: not incorporated in this summary. Fields not recorded or incorporated in this summary may still be present in the paper.
That’s the gist — a fine place to stop. This describes the studied groups, not personal suitability.
Understand the result
The full source record is retained in words with its study context and uncertainty. No derived comparison or combined axis is added.
- Who & when
- randomized trial. Population: Patients with an international normalized ratio (INR) between 4.5 and 10.0. Subject: oral vitamin K. Comparator: subcutaneous vitamin K. Source window: on the day after study drug administration. Scope: not incorporated in this summary. Fields not recorded or incorporated in this summary may still be present in the paper.
- Source
- PMID 12186515 · finding version 1
Each record retains its source-reported context and uncertainty.
Same finding version 1; paper version 2. Exact identity, status and limitations remain in this article.
Exact source-reported statements
randomized trial. Population: Patients with an international normalized ratio (INR) between 4.5 and 10.0. Subject: oral vitamin K. Comparator: subcutaneous vitamin K. Source window: on the day after study drug administration. Scope: not incorporated in this summary. Fields not recorded or incorporated in this summary may still be present in the paper.
- Authors reported OR 4.32; 95% CI 1.13 to 17.44; p = 0.015. No effect is calculated by the platform.
- Source-reported outcome counts: 15/26 versus 6/25. These denominators apply only to this outcome; no odds ratio is calculated.
- Shared treatment context: Warfarin therapy was withheld. The result does not establish either modality's standalone effect.
- Exposure increment: 1 mg.
- scope: not incorporated in this summary. No result-specific value is inferred from neighboring or subgroup results.
- adjustmentCovariates: not incorporated in this summary. This result-specific field remains unresolved; study-wide counts and nearby analyses are not assigned to it.
- therapeuticINRThreshold: not incorporated in this summary. This result-specific field remains unresolved; study-wide counts and nearby analyses are not assigned to it.
- bleedingBenefit: not incorporated in this summary. This result-specific field remains unresolved; study-wide counts and nearby analyses are not assigned to it.
Each record retains its source-reported context and uncertainty. No trial arms or new effect estimates are constructed.
Studied context
| Authors-reported finding | Authors reported OR 4.32; 95% CI 1.13 to 17.44; p = 0.015. No effect is calculated by the platform. |
|---|---|
| Authors-reported finding | Source-reported outcome counts: 15/26 versus 6/25. These denominators apply only to this outcome; no odds ratio is calculated. |
| Authors-reported finding | Shared treatment context: Warfarin therapy was withheld. The result does not establish either modality's standalone effect. |
| Authors-reported finding | Exposure increment: 1 mg. |
| Authors-reported finding | scope: not incorporated in this summary. No result-specific value is inferred from neighboring or subgroup results. |
| Authors-reported finding | adjustmentCovariates: not incorporated in this summary. This result-specific field remains unresolved; study-wide counts and nearby analyses are not assigned to it. |
| Authors-reported finding | therapeuticINRThreshold: not incorporated in this summary. This result-specific field remains unresolved; study-wide counts and nearby analyses are not assigned to it. |
| Authors-reported finding | bleedingBenefit: not incorporated in this summary. This result-specific field remains unresolved; study-wide counts and nearby analyses are not assigned to it. |
Limitations and extraction boundaries
- Source-authored comparison, pending human review; scientific eligibility remains separate.
- No clinical benefit, scale direction, unreported unit, dose, duration or adjustment is inferred.
- Shared arms, review participants and outcomes are not independent studies.
- Null results do not establish equivalence; these observations do not establish long-term safety.
You can stop here, or inspect the evidence and its original sources.
- Authors reported OR 4.32; 95% CI 1.13 to 17.44; p = 0.015. No effect is calculated by the platform.
- Source-reported outcome counts: 15/26 versus 6/25. These denominators apply only to this outcome; no odds ratio is calculated.
- Shared treatment context: Warfarin therapy was withheld. The result does not establish either modality's standalone effect.
- Exposure increment: 1 mg.
- scope: not incorporated in this summary. No result-specific value is inferred from neighboring or subgroup results.
- adjustmentCovariates: not incorporated in this summary. This result-specific field remains unresolved; study-wide counts and nearby analyses are not assigned to it.
- therapeuticINRThreshold: not incorporated in this summary. This result-specific field remains unresolved; study-wide counts and nearby analyses are not assigned to it.
- bleedingBenefit: not incorporated in this summary. This result-specific field remains unresolved; study-wide counts and nearby analyses are not assigned to it.
randomized trial. Population: Patients with an international normalized ratio (INR) between 4.5 and 10.0. Subject: oral vitamin K. Comparator: subcutaneous vitamin K. Source window: on the day after study drug administration. Scope: not incorporated in this summary. Fields not recorded or incorporated in this summary may still be present in the paper.
Source and extraction detail
- Finding revision
- finding:source-claim:12186515:820c92ac35f601c1c7a9:v1
- Finding version
- 1
- Finding content hash
- sha256:c5f98e0adb6addefd02f11f8cba655012744303b3c99dfbd7eedf57682954e4d
- Paper version
- 2
- Paper version content hash
- sha256:e24a52bbb07d2184edefb9d47c1cf83404f5b130012fe1d4da838947fe4122cd
- Source content hash
- sha256:4d50345c685932b850e4575f241ccc1f2e6612fce3fa4c3c2c1b95d0e9b55430
- Extraction policy
- known-pmid-four-semantic-comparisons-20261014-v1
- Extraction policy hash
- sha256:46926116a7071c64c0ebdef94f80a4a4e7dd177b0398996adbb4878c002d4451
- Extraction method version
- source-reported-records/v13-semantic-comparisons
- Field locators
- ownReport → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=12186515&rettype=abstract&retmode=text: abstract:888-1933; statistic → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=12186515&rettype=abstract&retmode=text: abstract:1717-1932; outcome → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=12186515&rettype=abstract&retmode=text: abstract:1818-1834
Source documents
- https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=12186515&rettype=abstract&retmode=text — sha256:4d50345c685932b850e4575f241ccc1f2e6612fce3fa4c3c2c1b95d0e9b55430 (ownReport → abstract:888-1933; statistic → abstract:1717-1932; outcome → abstract:1818-1834)
Read the full paper explanation
Optional audio and transcript
Audio reading
Read this exact transcript with an on-device browser voice. Checks the current public source version and starts only when you press Play; no audio provider or upload. Availability depends on this browser’s local voices.
Checking for a local voice…
Complete versioned transcript
Versioned snapshot of this displayed record. It may no longer be current; audio requires a successful current-version check.
therapeutic INRs Stable finding ID: finding:source-claim:12186515:820c92ac35f601c1c7a9. Finding version: 1. Revision: finding:source-claim:12186515:820c92ac35f601c1c7a9:v1. Content hash: sha256:c5f98e0adb6addefd02f11f8cba655012744303b3c99dfbd7eedf57682954e4d. Paper version: 2. Paper content hash: sha256:e24a52bbb07d2184edefb9d47c1cf83404f5b130012fe1d4da838947fe4122cd. AI-extracted — pending human review Source-authored record; platform synthesis is not enabled for this record. Publication status: published. Authors reported OR 4.32; 95% CI 1.13 to 17.44; p = 0.015. No effect is calculated by the platform. randomized trial. Population: Patients with an international normalized ratio (INR) between 4.5 and 10.0. Subject: oral vitamin K. Comparator: subcutaneous vitamin K. Source window: on the day after study drug administration. Scope: not incorporated in this summary. Fields not recorded or incorporated in this summary may still be present in the paper. Authors-reported finding: Authors reported OR 4.32; 95% CI 1.13 to 17.44; p = 0.015. No effect is calculated by the platform.. Authors-reported finding: Source-reported outcome counts: 15/26 versus 6/25. These denominators apply only to this outcome; no odds ratio is calculated.. Authors-reported finding: Shared treatment context: Warfarin therapy was withheld. The result does not establish either modality's standalone effect.. Authors-reported finding: Exposure increment: 1 mg.. Authors-reported finding: scope: not incorporated in this summary. No result-specific value is inferred from neighboring or subgroup results.. Authors-reported finding: adjustmentCovariates: not incorporated in this summary. This result-specific field remains unresolved; study-wide counts and nearby analyses are not assigned to it.. Authors-reported finding: therapeuticINRThreshold: not incorporated in this summary. This result-specific field remains unresolved; study-wide counts and nearby analyses are not assigned to it.. Authors-reported finding: bleedingBenefit: not incorporated in this summary. This result-specific field remains unresolved; study-wide counts and nearby analyses are not assigned to it.. Each record retains its source-reported context and uncertainty. Reported limitation: Source-authored comparison, pending human review; scientific eligibility remains separate. Reported limitation: No clinical benefit, scale direction, unreported unit, dose, duration or adjustment is inferred. Reported limitation: Shared arms, review participants and outcomes are not independent studies. Reported limitation: Null results do not establish equivalence; these observations do not establish long-term safety. Finding revision: finding:source-claim:12186515:820c92ac35f601c1c7a9:v1. Finding version: 1. Finding content hash: sha256:c5f98e0adb6addefd02f11f8cba655012744303b3c99dfbd7eedf57682954e4d. Paper version: 2. Paper version content hash: sha256:e24a52bbb07d2184edefb9d47c1cf83404f5b130012fe1d4da838947fe4122cd. Source content hash: sha256:4d50345c685932b850e4575f241ccc1f2e6612fce3fa4c3c2c1b95d0e9b55430. Extraction policy: known-pmid-four-semantic-comparisons-20261014-v1. Extraction policy hash: sha256:46926116a7071c64c0ebdef94f80a4a4e7dd177b0398996adbb4878c002d4451. Extraction method version: source-reported-records/v13-semantic-comparisons. Field locators: ownReport → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=12186515&rettype=abstract&retmode=text: abstract:888-1933; statistic → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=12186515&rettype=abstract&retmode=text: abstract:1717-1932; outcome → https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=12186515&rettype=abstract&retmode=text: abstract:1818-1834. Source document: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=12186515&rettype=abstract&retmode=text. Source hash: sha256:4d50345c685932b850e4575f241ccc1f2e6612fce3fa4c3c2c1b95d0e9b55430. Locators: ownReport: abstract:888-1933; statistic: abstract:1717-1932; outcome: abstract:1818-1834. Canonical paper: /studies/12186515. This is a reading of this version, not a clinical recommendation. Check the current paper page for updates.
Read this finding in study context →Original source · Bring into My Profile